Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 2/20 | 0.46 |
| ▸ | FEN1 | P39748 | 9/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 8/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1887973 | 0.79 | CYP11B2 (0.50) | MPLFEN1ALOX5APCYP11B2CYP11B1 | |
| SCHEMBL1888623 | 0.77 | FEN1 (0.46) | MPLFEN1ALOX5APIDO1APP | |
| SCHEMBL1892350 | 0.76 | KIF11 (0.52) | FEN1ALOX5APKIF11 | |
| SCHEMBL1885330 | 0.74 | L3MBTL1 (0.46) | MPLFEN1ALOX5APCYP11B2CYP11B1 | |
| SCHEMBL28315996 | 0.70 | HSD11B1 (0.50) | MPLFEN1ALOX5APIDO1CYP11B2 | |
| SCHEMBL1892790 | 0.70 | AHR (0.42) | MPLFEN1ALOX5APKIF11 | |
| SCHEMBL29778868 | 0.70 | CA1 (0.47) | MPLIDO1PDE2A | |
| SCHEMBL21603365 | 0.70 | CA1 (0.47) | MPLIDO1PDE2A | |
| SCHEMBL607667 | 0.69 | PDE2A (0.46) | MPLIDO1PDE2A | |
| SCHEMBL29453079 | 0.69 | PDE2A (0.46) | MPLIDO1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105543-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105543-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA5, CHRNA3, CHRM3 | MPL 4052/4885FEN1 4851/4885ALOX5AP 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.